> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.8% Of REGENXBIO As Gene-Therapy Milestones Approach
- URL: https://www.bullished.co/state-street-holds-4-8-of-regenxbio-as-gene-therapy-milestones-approach-c592fbe9/
- Published: 2026-11-10T15:18:09.000Z
- Updated: 2026-11-10T15:18:09.000Z
- Description: The passive holding comes with trial results expected this quarter and a Duchenne gene-therapy approval application planned for 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, RGNX, Industry: Healthcare

State Street reported a [4.8% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000715/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [REGENXBIO](https://www.bullished.co/tag/rgnx/), a clinical-stage developer of one-time gene therapies, in a Tuesday SEC ownership disclosure. The position covers 3,153,366 common shares as of September 30, with the company approaching late-stage trial results and a planned FDA approval application.

## A Passive Position, Not A Control Bid

State Street certified that its investment arose from ordinary business activity and that it does not hold the shares to change or influence REGENXBIO's control. It reported [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000715/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 3,081,970 shares and no sole voting authority.

REGENXBIO had a market capitalization of $534 million in Tuesday trading as of 10:03 a.m. ET.

## Cash Supports The Development Calendar

REGENXBIO reported third-quarter revenue of [$9.2 million](https://finance.yahoo.com/healthcare/articles/mizuho-names-top-smid-biotech-055141629.html?ref=bullished.co), against Mizuho's estimate of $5.9 million. Mizuho maintained its Outperform rating and lifted its price target to $18.00 from $7.71.

The company had [$251 million in cash](https://finance.yahoo.com/healthcare/articles/regenxbio-inc-rgnx-q3-2026-073333570.html?ref=bullished.co) in the third quarter and expects its funding to last into late 2027\. It has positive late-stage data for RGX-202, its Duchenne muscular dystrophy candidate, and is seeking accelerated approval.

## Retinal And Duchenne Programs Near Milestones

REGENXBIO's therapies use AAV vectors — non-replicating viruses that deliver genetic material — from its NAV Technology Platform. Its own pipeline targets retinal, neuromuscular and neurodegenerative diseases, and it manufactures therapies at its facility in Rockville, Maryland.

The company is developing sura-vec with AbbVie for wet age-related macular degeneration and diabetic retinopathy. Its programs with Nippon Shinyaku, RGX-121 and RGX-111, target the lysosomal storage disorders MPS II and MPS I. REGENXBIO also sublicenses its vectors to other developers, including Novartis, whose spinal muscular atrophy treatments Zolgensma and Itvisma use the platform.

REGENXBIO expects [late-stage sura-vec results](https://finance.yahoo.com/healthcare/articles/mizuho-names-top-smid-biotech-055141629.html?ref=bullished.co) for wet age-related macular degeneration in the fourth quarter of 2026\. It plans to submit its RGX-202 FDA approval application in the first quarter of 2027.

Those development milestones fall within the funding window REGENXBIO expects to extend into late 2027.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: REGENXBIO INC (RGNX)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000715/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Regenxbio Inc. (NASDAQ:RGNX) : Articles :: Law360](https://www.law360.com/companies/regenxbio-inc?article%5Frelated%5Fcontent=1&ref=bullished.co) — law360.com
- [Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...](https://finance.yahoo.com/healthcare/articles/regenxbio-inc-rgnx-q3-2026-073333570.html?ref=bullished.co) — Yahoo Finance
- [Mizuho names its top SMID biotech pick for November](https://finance.yahoo.com/healthcare/articles/mizuho-names-top-smid-biotech-055141629.html?ref=bullished.co) — Yahoo Finance
- [瑞穗證券公佈11月中小型生技板塊首選股](https://hk.finance.yahoo.com/news/%E7%91%9E%E7%A9%97%E8%AD%89%E5%88%B8%E5%85%AC%E4%BD%8811%E6%9C%88%E4%B8%AD%E5%B0%8F%E5%9E%8B%E7%94%9F%E6%8A%80%E6%9D%BF%E5%A1%8A%E9%A6%96%E9%81%B8%E8%82%A1-062141041.html?ref=bullished.co) — Yahoo Finance

### More on REGENXBIO

- [REGENXBIO Loses Royalty Revenue As Patent Expirations Cut Zolgensma Payments By $21.2 Million](https://www.bullished.co/regenxbio-loses-royalty-revenue-as-patent-expirations-cut-zolgensma-payments-by-21-2-a16037c7/)
- [REGENXBIO Chairman Kenneth Mills Resigns From Board After Taking CEO Job Elsewhere](https://www.bullished.co/regenxbio-chairman-kenneth-mills-resigns-from-board-after-taking-ceo-job-elsewhere-023eb9df/)
- [JPMorgan Reports 5.3% Passive Stake In REGENXBIO, 3,560,915 Shares, In SEC Filing](https://www.bullished.co/jpmorgan-reports-5-3-passive-stake-in-regenxbio-3-560-915-shares-in-sec-filing-af469bd6/)

[All REGENXBIO (RGNX) coverage →](https://www.bullished.co/tag/rgnx/)